Changxia Shao

570 total citations
35 papers, 398 citations indexed

About

Changxia Shao is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Changxia Shao has authored 35 papers receiving a total of 398 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 11 papers in Molecular Biology and 10 papers in Epidemiology. Recurrent topics in Changxia Shao's work include DNA Repair Mechanisms (6 papers), Cancer Genomics and Diagnostics (5 papers) and PARP inhibition in cancer therapy (5 papers). Changxia Shao is often cited by papers focused on DNA Repair Mechanisms (6 papers), Cancer Genomics and Diagnostics (5 papers) and PARP inhibition in cancer therapy (5 papers). Changxia Shao collaborates with scholars based in United States, China and South Korea. Changxia Shao's co-authors include Weimin Gao, Everardo Cobos, Chuanwen Lu, Lixia Chen, Fan Jin, Wei Zhou, Jouni Uitto, Yong Zhou, Qiujie Jiang and Tamara Snow and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Changxia Shao

33 papers receiving 396 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Changxia Shao United States 11 177 166 80 59 59 35 398
Hyewon Chung South Korea 13 116 0.7× 177 1.1× 21 0.3× 23 0.4× 72 1.2× 26 538
Marie Sébert France 13 123 0.7× 281 1.7× 36 0.5× 51 0.9× 28 0.5× 47 593
R. C. Horns United States 6 176 1.0× 159 1.0× 57 0.7× 35 0.6× 99 1.7× 11 411
Guoshun Shu China 9 179 1.0× 210 1.3× 35 0.4× 65 1.1× 127 2.2× 13 506
Chung‐Tai Yue Taiwan 10 220 1.2× 338 2.0× 43 0.5× 23 0.4× 83 1.4× 30 601
Maoxiang Qian China 11 118 0.7× 315 1.9× 77 1.0× 22 0.4× 22 0.4× 43 516
S.N. Kehlet Denmark 12 122 0.7× 114 0.7× 60 0.8× 26 0.4× 21 0.4× 17 386
Ming Hou China 14 70 0.4× 188 1.1× 33 0.4× 42 0.7× 15 0.3× 31 461
Carla Mazzone Italy 15 183 1.0× 479 2.9× 35 0.4× 23 0.4× 24 0.4× 47 951
Lijun Xu China 13 196 1.1× 156 0.9× 96 1.2× 34 0.6× 16 0.3× 36 505

Countries citing papers authored by Changxia Shao

Since Specialization
Citations

This map shows the geographic impact of Changxia Shao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changxia Shao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changxia Shao more than expected).

Fields of papers citing papers by Changxia Shao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changxia Shao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changxia Shao. The network helps show where Changxia Shao may publish in the future.

Co-authorship network of co-authors of Changxia Shao

This figure shows the co-authorship network connecting the top 25 collaborators of Changxia Shao. A scholar is included among the top collaborators of Changxia Shao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changxia Shao. Changxia Shao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tekin, Cumhur, et al.. (2024). Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer. Journal of Gynecologic Oncology. 35(6). e105–e105. 7 indexed citations
2.
Cai, Chen, Elisha J. Dettman, Wei Zhou, et al.. (2024). Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study. Future Oncology. 20(31). 2357–2370.
3.
Ma, Jiemin, Roman Groisberg, Changxia Shao, & Wenjun Zhong. (2024). Incidence of Undifferentiated Pleomorphic Sarcoma (UPS) in the United States. Sarcoma. 2024(1). 6735002–6735002. 1 indexed citations
4.
Shao, Changxia, Heng Zhou, Elisha J. Dettman, et al.. (2023). Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors. JCO Precision Oncology. 7(7). e2300195–e2300195. 1 indexed citations
5.
Shui, Irene M., Mehmet Burcu, Changxia Shao, et al.. (2023). Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases. Prostate Cancer and Prostatic Diseases. 27(4). 728–735. 7 indexed citations
6.
He, Jinghua, Changxia Shao, Siu L. Hui, et al.. (2019). Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study. Advances in Therapy. 37(1). 552–565. 4 indexed citations
7.
Shao, Changxia, et al.. (2018). Economic Burden of Advanced Cervical Cancer: A Systematic Literature Review. Value in Health. 21. S27–S27. 3 indexed citations
8.
9.
Li, Di, Jingli Wang, Jiayi Cui, et al.. (2016). Persistently high prevalence of primary resistance and multidrug resistance of tuberculosis in Heilongjiang Province, China. BMC Infectious Diseases. 16(1). 516–516. 13 indexed citations
10.
Shao, Changxia, Xiting Cao, Wei Zhou, et al.. (2016). Real-world treatment patterns in patients with Hodgkin lymphoma (HL) treated with brentuximab vedotin (BV) in the US.. Journal of Clinical Oncology. 34(15_suppl). e19019–e19019. 1 indexed citations
11.
Shao, Changxia, Jinan Liu, Wei Zhou, et al.. (2016). Utilization Patterns and Resource Use in Relapse/Refractory Hodgkin Lymphoma (rrHL) Patients Treated with Brentuximab Vedotin (BV). Blood. 128(22). 2377–2377. 3 indexed citations
12.
Jin, Liang, Qiujie Jiang, Changxia Shao, et al.. (2015). Genetic Heterogeneity of Pseudoxanthoma Elasticum: The Chinese Signature Profile of ABCC6 and ENPP1 Mutations. Journal of Investigative Dermatology. 135(5). 1294–1302. 24 indexed citations
13.
Wang, Congrong, Hui Zheng, Hongye Zhang, et al.. (2014). Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density. The Pharmacogenomics Journal. 15(2). 158–164. 19 indexed citations
14.
Zhou, Yong, Qiujie Jiang, Shunsuke Takahagi, Changxia Shao, & Jouni Uitto. (2013). Premature Termination Codon Read-Through in the ABCC6 Gene: Potential Treatment for Pseudoxanthoma Elasticum. Journal of Investigative Dermatology. 133(12). 2672–2677. 31 indexed citations
15.
Lu, Chuanwen, Changxia Shao, Everardo Cobos, Kamaleshwar P. Singh, & Weimin Gao. (2012). Chemotherapeutic Sensitization of Leptomycin B Resistant Lung Cancer Cells by Pretreatment with Doxorubicin. PLoS ONE. 7(3). e32895–e32895. 28 indexed citations
16.
Chen, Lixia, Changxia Shao, Everardo Cobos, Jia-Sheng Wang, & Weimin Gao. (2010). 4-(Methylnitro-Samino)-1-(3-Pyridyl)-1-Butanone Induces CRM1-Dependent P53 Nuclear Accumulation in Human Bronchial Epithelial Cells. Toxicological Sciences. 116(1). 206–215. 10 indexed citations
17.
Shao, Changxia, Chuanwen Lu, Lixia Chen, et al.. (2010). p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemotherapy and Pharmacology. 67(6). 1369–1380. 31 indexed citations
18.
Shao, Changxia, Lixia Chen, Chuanwen Lu, Chwan‐Li Shen, & Weimin Gao. (2010). A gel-based proteomic analysis of the effects of green tea polyphenols on ovariectomized rats. Nutrition. 27(6). 681–686. 25 indexed citations
19.
Chen, Lixia, et al.. (2009). Curcumin modulates eukaryotic initiation factors in human lung adenocarcinoma epithelial cells. Molecular Biology Reports. 37(7). 3105–3110. 15 indexed citations
20.
Shao, Changxia, Songming Chen, Lixia Chen, et al.. (2009). Antibody microarray analysis of serum glycans in esophageal squamous cell carcinoma cases and controls. PROTEOMICS - CLINICAL APPLICATIONS. 3(8). 923–931. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hyewon Chung Breakdown of academic impact, for papers by Marie Sébert Breakdown of academic impact, for papers by R. C. Horns Breakdown of academic impact, for papers by Guoshun Shu Breakdown of academic impact, for papers by Chung‐Tai Yue Breakdown of academic impact, for papers by Maoxiang Qian Breakdown of academic impact, for papers by S.N. Kehlet Breakdown of academic impact, for papers by Ming Hou Breakdown of academic impact, for papers by Carla Mazzone Breakdown of academic impact, for papers by Lijun Xu
Rankless by CCL
2026